AR038354A1 - Inhibidores de integrina alphav beta6 - Google Patents
Inhibidores de integrina alphav beta6Info
- Publication number
- AR038354A1 AR038354A1 ARP030100360A ARP030100360A AR038354A1 AR 038354 A1 AR038354 A1 AR 038354A1 AR P030100360 A ARP030100360 A AR P030100360A AR P030100360 A ARP030100360 A AR P030100360A AR 038354 A1 AR038354 A1 AR 038354A1
- Authority
- AR
- Argentina
- Prior art keywords
- oar
- monosubstituted
- hal
- unsubstituted
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Abstract
Los compuestos son nuevos inhibidores de integrina que inhiben, de preferencia, el receptor de la integrina alfavbeta6. También se reivindica el proceso para prepararlos, medicamentos, usos de los compuestos para preparar medicamentos útiles para trastornos circulatorios, fibrosis pulmonar, embolia pulmonar, trombosis, infarto cardíaco, arteriosclerosis, apoplejía, angina de pecho, fibrosis, enfermedades tumorales, osteoporosis, inflamación, trastornos oftalmológicos, psoriasis, esclerosis múltiple, infección bacteriana y fúngica entre otras. Reivindicación 1: Compuestos de la fórmula (1), donde: R1, R1' y R1'' son H, A, Ar, Het1, Hal, NO2, CN, OR4, COA, NHCOA, N(CHO), NR4, COOR4 y/o CONHR42; R2 es A, AR, (CH2)mXA, (CH2)mOH, (CH2)mNH2, (CH2)mNHA, (CH2)mNA2, (CH2)mNHCOA, (CH2)mNO2, (CH2)mCOOR1, (CH2)mCONH2, (CH2)mX(CH2)oAr, (CH2)m X(CH2)oCHAr2, (CH2)mX(CH2)oCAr3, (CH2)mXCOYA, (CH2)mXCOY(CH2)oAr, (CH2)mX(CH2)oHet1, (CH2)mX(CH2)oCHHet12, (CH2)mX(CH2)oCHet13, (CH2)mX(CH2)oYA, (CH2)mX(CH2)oNHCOA, (CH2)mNHCOHR2',(CH2)mCH2A, (CH2)mCHA2, (CH2)mCA3, (CH2)mAr, (CH2)mCHAr2, (CH2)mCAr3, (CH2)mHet1, (CH2)mCHHet12, (CH2)mCHet13, (CH2)mcicloalquilo, (CH2)m-NH-C(=NH)-NH2 ó (CH2)m-(HN=)C-NH2, donde X e Y, independientemente entre sí, pueden ser S, O, S=O, SO2 ó NH, donde, si R2 = (CH2)mXCOYA ó (CH2)mXCOY(CH2)oAr, X e Y no pueden ser S=O ó SO2; R2' es H ó A; R2 y R2' pueden ser juntos, de modo alternativo, -(CH2)p-; R3 es H2N-C(=NH)-,H2N-C(=NH)-NH-, A-C(=NH)-NH-, Het2- ó Het2-NH-, donde los grupos amino primarios también pueden estar provistos de grupos de protección amino convencionales; R4 es H, A, Het1, Hal, NO2 ó CN; A es alquilo C1-8; B es H ó A; Ar es fenilo, naftilo, antranilo o bifenilo, cada uno de los cuales está insustituido o monosustituido o polisustituido por Hal, A, OA, OH, CO-A, CN, COOA, COOH, CONH2, CONHA, CONA2, CF3, OCF3 ó NO2; Het 1 es un radical heterocíclico aromático monocíclico ó bicíclico que tiene de 1 a 3 átomos de N, O y/o S, que puede estar insustituido ó monosustituido ó disustituido por F, Cl, Br, A, OA, SA, OCF3, -CO-A, CN, COOA, CONH2, CONHA, COA2, NA2 ó NO2; Het 2 es un radical heterocíclico monocíclico o bicíclico que tiene de 1 a 4 átomos de N, que puede estar insustituido o monosustituido o disustituido por NH2, NHA ó A; m es 0, 1, 2, 3, 4, 5, 6 u 8; n es 1, 2, 3, 4, 5, ó 6; o es 0, 1, 2, ó 3; p es 2, 3, 4 ó 5; sus estereoisómeros y sus sales y solvatos fisiológicamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10204789A DE10204789A1 (de) | 2002-02-06 | 2002-02-06 | Inhibitoren des Integrins alpha¶v¶beta6 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038354A1 true AR038354A1 (es) | 2005-01-12 |
Family
ID=27588391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100360A AR038354A1 (es) | 2002-02-06 | 2003-02-05 | Inhibidores de integrina alphav beta6 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7138417B2 (es) |
EP (1) | EP1472224B1 (es) |
JP (1) | JP4589628B2 (es) |
CN (1) | CN1628101A (es) |
AR (1) | AR038354A1 (es) |
AU (1) | AU2003208325B2 (es) |
CA (1) | CA2475930C (es) |
DE (1) | DE10204789A1 (es) |
ES (1) | ES2389300T3 (es) |
PL (1) | PL371217A1 (es) |
RU (1) | RU2004126944A (es) |
WO (1) | WO2003066594A2 (es) |
ZA (1) | ZA200407035B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
WO2004052277A2 (en) * | 2002-12-05 | 2004-06-24 | Wisconsin Alumni Research Foundation | Anthrax antitoxins |
KR20060109247A (ko) * | 2005-04-13 | 2006-10-19 | 엘지전자 주식회사 | 베이스 레이어 픽처를 이용하는 영상신호의 엔코딩/디코딩방법 및 장치 |
WO2006089114A2 (en) * | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating an anthrax toxin mediated condition |
JP5637855B2 (ja) * | 2007-11-08 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | 蛋白尿症の治療のための方法及び組成物 |
WO2012085081A1 (en) | 2010-12-22 | 2012-06-28 | Basf Se | Sulfoximinamide compounds for combating invertebrate pests ii |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP4233902A3 (en) | 2016-12-14 | 2024-02-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
AU2018229275B2 (en) | 2017-02-28 | 2021-12-23 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
WO2018160522A1 (en) | 2017-02-28 | 2018-09-07 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
TW202035400A (zh) | 2018-08-29 | 2020-10-01 | 美商莫菲克醫療股份有限公司 | 抑制αvβ6整合素 |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3087828A (en) | 1961-06-28 | 1963-04-30 | Du Pont | Nacreous pigment compositions |
US3658552A (en) | 1969-05-22 | 1972-04-25 | Gen Foods Corp | Clouding agent |
BE759469A (fr) | 1969-11-29 | 1971-05-26 | Merck Patent Gmbh | Pigment a brillant nacre et leurs procedes de |
US3875890A (en) | 1973-02-06 | 1975-04-08 | Cava Carl | Side warning device for cycles |
DE2429762C2 (de) | 1974-06-21 | 1984-08-30 | Merck Patent Gmbh, 6100 Darmstadt | Farbstoffhaltige Glanzpigmente |
US4968351A (en) | 1988-11-02 | 1990-11-06 | The Mearl Corporation | Nacreous pigments colored by adsorbed dyes |
GB2257433A (en) | 1991-07-12 | 1993-01-13 | Bipin Chandra Muljibhai Patel | Dental material usable as e.g. fissure sealant |
GB9115154D0 (en) | 1991-07-12 | 1991-08-28 | Patel Bipin C M | Sol-gel composition for producing glassy coatings |
JP2835796B2 (ja) | 1992-02-06 | 1998-12-14 | メルク・ジヤパン株式会社 | 新規な薄片状顔料 |
DE4212304A1 (de) * | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
DE4215367A1 (de) | 1992-05-08 | 1993-11-11 | Gerhard Ruth Gmbh & Co Kg | Farbpigmentpartikel für eine Lebensmittelfarbe |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
FR2745493B1 (fr) | 1996-03-01 | 1998-04-24 | Oreal | Composition anhydre sous forme de poudre et utilisation d'un ester comme liant de poudres |
DE19618564A1 (de) | 1996-05-09 | 1997-11-13 | Merck Patent Gmbh | Plättchenförmiges Titandioxidpigment |
US5885342A (en) | 1997-05-09 | 1999-03-23 | Engelhard Corporation | Blended nacreous pigments, colorants and adjuvants |
GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
US6139615A (en) | 1998-02-27 | 2000-10-31 | Engelhard Corporation | Pearlescent pigments containing ferrites |
PL343406A1 (en) * | 1998-04-10 | 2001-08-13 | Searle & Co | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
US6576637B1 (en) | 1999-02-20 | 2003-06-10 | Merck Patent Gmbh | β-alanine derivatives |
US6165260A (en) | 1999-03-30 | 2000-12-26 | Engelhard Corporation | Pearlescent pigments exhibiting color travel |
PL352777A1 (en) * | 1999-04-28 | 2003-09-08 | Basf Aktiengesellschaft | Integrin receptor antagonists |
US6471762B1 (en) | 2000-08-23 | 2002-10-29 | Engelhard Corp. | Bonded metal-hydroxide-organic composite polymer films on lamellar pigments |
DE10063173A1 (de) | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
-
2002
- 2002-02-06 DE DE10204789A patent/DE10204789A1/de not_active Withdrawn
-
2003
- 2003-01-15 PL PL03371217A patent/PL371217A1/xx unknown
- 2003-01-15 CA CA2475930A patent/CA2475930C/en not_active Expired - Fee Related
- 2003-01-15 WO PCT/EP2003/000327 patent/WO2003066594A2/de active Application Filing
- 2003-01-15 JP JP2003565968A patent/JP4589628B2/ja not_active Expired - Fee Related
- 2003-01-15 ES ES03706358T patent/ES2389300T3/es not_active Expired - Lifetime
- 2003-01-15 US US10/503,616 patent/US7138417B2/en not_active Expired - Fee Related
- 2003-01-15 RU RU2004126944/04A patent/RU2004126944A/ru not_active Application Discontinuation
- 2003-01-15 EP EP03706358A patent/EP1472224B1/de not_active Expired - Lifetime
- 2003-01-15 AU AU2003208325A patent/AU2003208325B2/en not_active Ceased
- 2003-01-15 CN CNA038034476A patent/CN1628101A/zh active Pending
- 2003-02-05 AR ARP030100360A patent/AR038354A1/es unknown
-
2004
- 2004-10-02 ZA ZA200407035A patent/ZA200407035B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200407035B (en) | 2006-06-28 |
CA2475930A1 (en) | 2003-08-14 |
JP4589628B2 (ja) | 2010-12-01 |
DE10204789A1 (de) | 2003-08-14 |
US20050153902A1 (en) | 2005-07-14 |
AU2003208325A1 (en) | 2003-09-02 |
RU2004126944A (ru) | 2006-02-10 |
WO2003066594A2 (de) | 2003-08-14 |
CN1628101A (zh) | 2005-06-15 |
PL371217A1 (en) | 2005-06-13 |
ES2389300T3 (es) | 2012-10-25 |
EP1472224B1 (de) | 2012-07-11 |
AU2003208325B2 (en) | 2009-04-30 |
JP2005519929A (ja) | 2005-07-07 |
CA2475930C (en) | 2011-09-27 |
EP1472224A2 (de) | 2004-11-03 |
WO2003066594A3 (de) | 2003-11-27 |
US7138417B2 (en) | 2006-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR038354A1 (es) | Inhibidores de integrina alphav beta6 | |
PE20040696A1 (es) | Derivados de acido mandelico como inhibidores de la formacion de factores de coagulacion | |
NO20053340L (no) | Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1). | |
PA8491101A1 (es) | Derivados de 4-fenil-piridin. | |
HUP0303514A2 (hu) | AlfavBéta6 integrin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR002723A1 (es) | Compuestos derivados de quinazolina y procedimiento para prepararlos, compuesto intermediarios utiles en dicho procedimiento, su uso | |
RU2008119412A (ru) | N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы | |
DE69332754D1 (de) | Anregende Aminosäuren Antagonisten | |
BRPI0511186A (pt) | composto, pró-droga do composto, composição farmacêutica, uso do composto, e, processo para preparar o composto | |
AR053987A1 (es) | Derivados de malonamida. proceso de obtencion y composiciones farmaceuticas. | |
PE20070171A1 (es) | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa | |
LU90011I2 (fr) | Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil | |
AR032482A1 (es) | Uso de tienopirimidinas | |
PE20061155A1 (es) | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas | |
DK0858461T3 (da) | Kondenserede tropanderivater som neurotransmittergenoptagelsesinhibitorer | |
DK0686142T3 (da) | Polyaminderivater som radioprotektive midler | |
AR029343A1 (es) | USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN | |
AR013503A1 (es) | Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion | |
AR029152A1 (es) | Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i | |
DK0545845T3 (da) | Imidazolforbindelser, deres fremstilling og anvendelse som ca-kanal blokkere | |
AR010899A1 (es) | Oxazolidinonas, un procedimiento para su preparacion, el empleo de las mismas para preparar un medicamento, medicamentos y preparaciones farmaceuticasque las contienen y un procedimiento para obtener estas preparaciones farmaceuticas. | |
DK0498331T3 (da) | N-(Aryloxyalkyl)-heteroaryl-8-azabicyclo(3.2.1)octaner, mellemprodukter og en fremgangsmåde til fremstilling deraf samt deres anvendelse som lægemidler | |
NO955197D0 (no) | Nye karbosykliske nucleoside midler som er anvendbare som inhibitorer av pro-inflammatoriske cytokiner | |
AR037757A1 (es) | Fenilalquinos | |
EA200000116A1 (ru) | Противогрибковые соединения на основе 2,4,4-тризамещенных-1,3-диоксоланов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |